Zacks Research Weighs in on Gilead Sciences FY2025 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities researchers at Zacks Research raised their FY2025 earnings per share (EPS) estimates for Gilead Sciences in a research report issued to clients and investors on Monday, December 9th. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutical company will post earnings of $7.03 per share for the year, up from their prior forecast of $6.91. The consensus estimate for Gilead Sciences’ current full-year earnings is $4.35 per share. Zacks Research also issued estimates for Gilead Sciences’ Q4 2025 earnings at $1.81 EPS and FY2026 earnings at $7.50 EPS.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. During the same period last year, the company earned $2.29 earnings per share. The company’s quarterly revenue was up 7.0% on a year-over-year basis.

A number of other equities research analysts also recently issued reports on the company. Daiwa America raised Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Robert W. Baird boosted their target price on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. BMO Capital Markets raised their price target on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Citigroup began coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They set a “buy” rating and a $125.00 price target on the stock. Finally, Maxim Group downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Twelve research analysts have rated the stock with a hold rating, twelve have given a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $96.43.

Gilead Sciences Stock Up 0.3 %

Shares of GILD opened at $91.86 on Thursday. The firm has a market cap of $114.48 billion, a PE ratio of 1,026.44, a price-to-earnings-growth ratio of 2.38 and a beta of 0.18. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The company’s fifty day moving average is $89.82 and its two-hundred day moving average is $79.26. Gilead Sciences has a fifty-two week low of $62.07 and a fifty-two week high of $98.90.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be given a dividend of $0.77 per share. The ex-dividend date is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.35%. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now owns 80,801 shares in the company, valued at approximately $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the sale, the chief financial officer now owns 138,919 shares of the company’s stock, valued at $12,886,126.44. This trade represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 447,234 shares of company stock valued at $41,288,086. Company insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors and hedge funds have recently modified their holdings of GILD. Exome Asset Management LLC acquired a new stake in Gilead Sciences during the 3rd quarter worth about $4,192,000. Brass Tax Wealth Management Inc. purchased a new stake in shares of Gilead Sciences in the 3rd quarter valued at approximately $242,000. Garden State Investment Advisory Services LLC acquired a new position in Gilead Sciences during the third quarter valued at $221,000. Franklin Resources Inc. increased its holdings in shares of Gilead Sciences by 22.8% in the 3rd quarter. Franklin Resources Inc. now owns 2,241,354 shares of the biopharmaceutical company’s stock valued at $190,611,000 after purchasing an additional 416,379 shares during the period. Finally, Tri Ri Asset Management Corp acquired a new stake in shares of Gilead Sciences during the third quarter worth approximately $3,380,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.